Market Opportunities | Delve into Insmed's strategy in targeting underserved patient populations, potentially driving significant revenue growth and market leadership in rare diseases |
Financial Outlook | Analysts project EPS of -5.57 and -4.93 for the next two fiscal years, with price targets ranging from $80 to $109, reflecting strong growth potential |
Pipeline Potential | Explore Insmed's promising pipeline, including brensocatib for bronchiectasis, with projected U.S. sales of up to $3.8 billion by 2034 |
Rare Disease Pionee | Insmed's focus on serious and rare diseases positions it as a significant player in niche markets with high unmet medical needs and potential for premium pricing |

Metrics to compare | INSM | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipINSMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −23.0x | −2.6x | −0.5x | |
PEG Ratio | 1.51 | −0.09 | 0.00 | |
Price / Book | 39.8x | 1.6x | 2.6x | |
Price / LTM Sales | 48.5x | 10.8x | 3.2x | |
Upside (Analyst Target) | 56.0% | 303.7% | 48.8% | |
Fair Value Upside | Unlock | 10.2% | 6.9% | Unlock |